The intestinal incretin hormone glucagon-like peptide I (GLP-I) inhibits gastric motility and secretion in normal, but not in vagotomized subjects, pointing to a centrally mediated effect. Therefore, our aim was to study the availability of rat brain GLP-I receptors to peripherally injected 125 T he intestinal hormone glucagon-like peptide I (GLP-I) is a powerful stimulant of insulin secretion in mammals (1,2). The peptide is released after a meal from the intestinal L-cells (3,4) and stimulates insulin through binding to the GLP-I receptor on the P-cells in the pancreas (5). In physiological concentrations, GLP-I inhibits pentagastrin-stimulated, as well as meal-induced, gastric acid secretion and inhibits gastric emptying in normal humans (6). It also strongly inhibits cephalic-phase vagally mediated gastric acid secretion in humans (7). In vagotomized subjects, however, GLP-I does not affect pentagastrin-stimulated gastric acid secretion (8). Thus, in humans, the effect of GLP-I on gastric acid secretion is probably centrally mediated. Cerebroventricular, but not intraperitoneal, administration of GLP-I has been shown to inhibit food intake (9-11) and drinking (11) in normal rats. In addition, intraperitoneal administration of GLP-I has been reported to inhibit drinking behavior in rats (11). Specific binding of GLP-I to sections of rat brain has been shown by several groups (9,12). The major GLP-I binding regions, identified either by receptor autoradiography or by using homogenates of rat brain, are the hypothalamus, the thalamus, the septal area, the subfornical organ, and several areas in the brain stem, such as the nucleus of the solitary tract and the area postrema (9, (11) (12) (13) (14) . The brain GLP-I receptor, which is identical to the p-cell receptor, has recently been cloned (15). However, most of the GLP-I binding sites detected by receptor autoradiography are located in areas endowed with a blood-brain barrier. Thus, the ligand for most of these binding sites is probably GLP-I produced in the brainstem (16, 17) . On the other hand, it has been shown that certain peptides (e.g., insulin) can be transported across the blood-brain barrier by receptor-mediated transcytosis (18). In addition, in vivo tracer studies have shown that parts of the so-called blood-brain barrier-free areas in the brain are not freely accessible to proteins and peptides because of a barrier caused by leptomeningeal cell processes in these areas (19). To examine whether any of the GLP-I binding sites in the rat brain are accessible to peripheral GLP-I, we injected 125 I-labeled GLP-I with or without excess amounts of unlabeled GLP-I intracardially into normal anesthetized Wistar rats and examined brain sections by light microscopical autoradiography.
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RESEARCH DESIGN AND METHODS
The animal studies were approved by the local animal committee of Copenhagen, Denmark. Seven normal female Wistar rats (200-225 g each) were studied. The rats were anesthetized with an intraperitoneal methohexital injection of 5 mg/100 g body wt (Brietal, Lilly), intubated, and ventilated with pure oxygen. The thorax was opened and the descending aorta was lightly clamped while 125 I-GLP-I, either alone (n = 4) or together with unlabeled GLP-I (n = 3), was injected slowly into the left ventricle of the heart. We injected 0.5 ml of 126 I-GLP-I(7-36) amide into each animal (specific activity 0.08 MBq/pmol) in 0.01 mol/1 Tris and 0.005 mol/1 H3PO4 containing 1% human serum albumin (reinst, trocken; Behringwercke, Marburg, Germany). The tracer was labeled and purified by high-pressure liquid chromatography as previously described (20) . The radioactive concentration of the labeled peptide injected was 1.1 MBq/ml. In the control animals, the same amount of 125 I-GLP-I was injected together with 1 mg unlabeled GLP-I(7-36) amide (Peninsula, St. Helens, U.K.). Five minutes after the injection, the animals were fixed by perfusion with 2% glutaraldehyde in 0.04 mol/1 phosphate buffer, pH 7.4. The brains were removed and kept in fixative overnight. Before sectioning, the brains were washed for 36 h in 0.04 mol/1 phosphate buffer, pH 7.4, containing 20% sucrose. Every sixth 10-|xm cryostat section of each brain was adhered onto gelatin-coated glass slides and dried. The slides were dipped in film emulsion (Ilford K2, Cheshire, U.K.; diluted twice with distilled water), left for 5 weeks at -80°C, and then developed. Finally, the slides were counterstained lightly with hematoxylin and examined by light microscopy. 
RESULTS AND DISCUSSION

Specific
125
I-GLP-I labeling was found in two distinct areas of the rat brain: the subfornical organ and the area postrema. In the subfornical organ, uniform dense labeling was seen throughout the organ (Fig. 1) .
I-GLP-I labeling was also found on cells located in the periphery of the area postrema. In addition, a few labeled cells were found in the underlying commissural nucleus (Fig. 1) . All 125 I-GLP-I labeling was totally displaceable with unlabeled GLP-I (Fig. 1) . No binding was seen in any other areas of the rat brain.
The capillaries of both the subfornical organ and the area postrema are fenestrated and lack the endothelial tight junctions associated with the blood-brain barrier (21) . We found the most intense 125 I-GLP-I labeling in the subfornical organ (Fig. 1) . The subfornical organ is a small tubercle attached to the fornix in the roof of the third ventricle. From the subfornical organ, humoral information is conducted over a neural circuit of structures having sensory, motor, autonomic, and endocrinological roles that can influence water balance (22, 23) . It has previously been shown that intraperitoneal administration of GLP-I inhibits drinking behavior in rats (11) . Thus, this effect of peripherally administered GLP-I might be mediated via GLP-I receptors in the subfornical organ. Neurons expressing at least a dozen different neuropeptides and amines have been localized in the subfornical organ (22), although we did not address the question of the transmitter content in the cells on which the GLP-I receptors are present in this study.
The area postrema is a small brainstem structure on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle. Like the subfornical organ, the area postrema is a circumventricular organ with a high capillary density and permeability. The area postrema receives afferent input from the hypothalamus and from vagal fibers (22, 24, 25) . The efferent projections from the area postrema are to structures regarded as major relay nuclei (nucleus tractus solitarius and the lateral parabrachial nucleus) for hypothalamic neurosecretory neurons, for vagal motor neurons, and for ascending visceral inputs to the forebrain (22, 25) . Thus, the area postrema has been implicated as a major station for the processing of visceral sensory information involved primarily in eliciting rapid homeostatic responses to fluid and nutrient imbalances (22, 25) . Neurons expressing several different neuropeptides and amines in the area postrema have been described (22) , but in this study, we did not try to elucidate the transmitter content in the cells on which GLP-I binding was present.
The structure of the brain GLP-I receptor has been deduced by Wei et al. (15) , who found it to be identical to the (3-cell GLP-I receptor. Cerebroventricular, but not intraperitoneal, administration of GLP-I has been shown by several groups to inhibit food intake, probably through interaction with hypothalamic nuclei (9) (10) (11) . In this study, we did not see any indication of GLP-I crossing the blood-brain barrier. Thus, these effects probably illustrate the effect of GLP-I produced in the brainstem because peripherally produced GLP-I does not have access to the hypothalamus because this structure is protected by the blood-brain barrier.
It is well established that gut-derived GLP-I (which seems to be identical to brain GLP-I [1, 2, 16] ) stimulates insulin secretion through binding to specific receptors on the 3-cells (1, 2, 5) . Gut-derived GLP-I also inhibits gastric acid secretion, gastric emptying, and pancreatic enzyme secretion in normal humans (6, 7) . These gastrointestinal effects of GLP-I are not found in vagotomized subjects, pointing to a possible centrally mediated effect (8) . The inhibitory effect of GLP-I on gastric emptying is consistent with a role for GLP-I in the regulation of food intake. In addition, GLP-I injected intraperitoneally has been shown to inhibit drinking behavior in rats (11) . These effect could be mediated by the GLP-I receptors located in the subfornical organ and the area postrema.
In conclusion, we have shown GLP-I receptors accessible to peripheral GLP-I in the subfornical organ and the area postrema in the rat. These distinct localizations are consistent with potential roles for GLP-I to participate in the regulation of appetite, fluid homeostasis, and autonomic function.
